E-ISSN 2534-9821
 

Original Research 


Gestational trophoblastic diseases-diagnosis and risk factors: A case series

Uzel Kemine, Basol Gulfem, Kale Ahmet, Lakhno Igor.

Abstract
Aim of study:
The aim of our study is to investigate the role of the age, gravida, parity, blood group in the development of GTD also significance of the b-hCG levels and pelvic ultrasonography in diagnosis and treatment of this patients. Comparisons of GTD incidence between Turkey and different regions of the world.
Materials and Metods:
This retrospective study included 1813 patients which underwent vacuum aspiration from 2010 to2018 years in Derince Training and Research Hospital, Kocaeli, Turkey. Files of 18 patients compatible with GTD in pathology were retrospectively scanned.
Result:
As a result of the study, the average age of patients were27.06, pathology results were found in 14 patients (77,7%) partial mol, in 2 patients (11,1%) complete mol, invasive mol in 1 patient (5,6%) and choriocarcinoma in 1 patient (5,6%). In these cases, 1 case of lung metastasis and 3 patients received chemotherapy treatment. There was no mortality associated with the disease during follow-up.

Conclusion:
The calculated GTD incidence was 1,5 per 1000 births. Radiologist plays a main role in the first diagnosis of GTD and basis disease management and early finding of its complications. Although serum b- hCG is a useful biochemical marker for GTD. Ultrasound is the initial line radiological examination in approving the diagnosis of GTD in a case suspected on the basis of clinical detections and b- hCG levels. We believe that diagnosis, adequate treatment and follow-up will make easy the cure of GTD and the incidence can be calculated more exacly by performing wide community-based studies.

Key words: gestational trophoblastic disease, hydatidiform moles, molar pregnancy, gestational neoplasia


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Uzel Kemine
Articles by Basol Gulfem
Articles by Kale Ahmet
Articles by Lakhno Igor
on Google
on Google Scholar


REFERENCES
1. Perez-Costas E, Melendez-Ferro M, Roberts RC. Basal ganglia pathology in Schizophrenia: Dopamine connections and Anomalies. J Neurochem 2010; 113:287-302.

http://dx.doi.org/10.1111/j.1471-4159.2010.06604.x

[Pubmed]    [PMC Free Fulltext]   


2. Delay J, Deniker P, Harl JM. Therapeutic use in psychiatry of phenothiazine of central elective action0 (4560RP). Ann Med Psychol (Paris) 1952;110:112-7.


3. Carlsson A, Lindqvist M. Effect of Chlorpromazine or Haloperidol on formation of 3methoxytyramine and Normetanephrine in Mouse Brain. Acta Pharmacol Toxicol (Copenh). 1963;20:140-4.

http://dx.doi.org/10.1111/j.1600-0773.1963.tb01730.x


4. Cresse I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and Pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3.

http://dx.doi.org/10.1126/science.3854


5. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptics/dopamine receptors. Nature 1976;261:717-9.

http://dx.doi.org/10.1038/261717a0

[
Pubmed]   


6. Seeman P, Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A 2000;97:7673-5.

http://dx.doi.org/10.1073/pnas.97.14.7673

[
Pubmed]    [PMC Free Fulltext]   


7. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-86.

http://dx.doi.org/10.1016/0893-133X(88)90012-7


8. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptulization. Am J Psychiatry 1991;148:1474-86.

[
Pubmed]   


9. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-The final common Pathway. Schizophr Bull 2009;35:549-62.

http://dx.doi.org/10.1093/schbul/sbp006

[
Pubmed]    [PMC Free Fulltext]   


10. Patel JC, Witkovsky P, Avshalumov MV, Rice ME. Mobilization of calcium from intracellular stores facilitates somatodendritic dopamine release. J Neurosci 2009;29:6568-79.

http://dx.doi.org/10.1523/JNEUROSCI.0181-09.2009

[
Pubmed]    [PMC Free Fulltext]   


11. Olivera BM, Miljanich GP, Ramachandran J, Adams ME. Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins. Annu Rev Biochem 1994;63:823-67.

http://dx.doi.org/10.1146/annurev.bi.63.070194.004135

[
Pubmed]   


12. Herdon H, Nahorski SR. Investigations of the roles of dihydropyridine and omega-conotoxin sensitive calcium channels in mediating depolarization evoked dopamine release from striatal slices. Naunyn schmiedebergs Arch Pharmacol 1989;340:36-40.

http://dx.doi.org/10.1007/BF00169204

[
Pubmed]   


13. Blake BL, Muehlmann AM, Egami K, Breese GR, Devine DP, Jinnah HA. Nifedipine suppresses self-injurious behaviors in animals. Dev Neurosci 2007;29:241-50.

http://dx.doi.org/10.1159/000096414

[
Pubmed]    [PMC Free Fulltext]   


14. Khanzode SD, Mahakalkar SM, Belorkar NR, Kharkar VT, Manekar MS. Effect of Pretreatment of some calcium channel blockers on catalepsy and stereotypic behavior in rats. Indian J Physiol Pharmacol 1996;40:159-62.

[
Pubmed]   


15. Kozlovskiĭ VL, Prakh'e IV, Kenunen OG. The influence of calcium channel blockers on the effects of haloperidol and phenamine in mice and rats. Eksp Klin Farmakol 1996;59:12-5.

[
Pubmed]   


16. Alessi NE, Walden M, Hsieh PS. Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: a case study. J Clin Psychiatry 1989;50:103-4.

[
Pubmed]   


17. Marinelli M, Rudick CN, HuXT, White FJ. Excitability of dopamine neurons: modulation and physiological consequences. CNS Neurol Disord Drug Targets 2006;5:79-97.

http://dx.doi.org/10.2174/187152706784111542

[
Pubmed]   


18. Suddath RL, Straw GM, Freed WJ, Bigelow LB, Kirch DG, Wyatt RJ. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia. Pharmacol Biochem Behav 1991;39:743-5.

http://dx.doi.org/10.1016/0091-3057(91)90157-W


19. Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in treatment of Tardive dyskinesia. J Clin Psychopharmacol 1990;10:414-6.

http://dx.doi.org/10.1097/00004714-199010060-00006

[
Pubmed]   


20. Wadenburg ML. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 1996;20:325-39.

http://dx.doi.org/10.1016/0149-7634(95)00057-7


21. Wadenburg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev 1999;23:851-62.

http://dx.doi.org/10.1016/S0149-7634(99)00037-8


22. Cook L, Weidley E. Behavioral effects of some psychopharmacological agents. Ann N Y Acad Sci 1957; 66:740-52.

http://dx.doi.org/10.1111/j.1749-6632.1957.tb40763.x

[
Pubmed]   


23. Costall B, Naylor RJ. Mesolimbic involvement with behavioral effects indicating antipsychotic activity. Eur J Pharmacol 1974;27:46-58.

http://dx.doi.org/10.1016/0014-2999(74)90201-5


24. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001;25:633-41.

http://dx.doi.org/10.1016/S0893-133X(01)00261-5


25. Biala G. Haloperidol induced catalepsy is influenced by calcium channel antagonists Acta Pol Pharm 2000;57:233-7.

PMid:11143713

How to Cite this Article
Pubmed Style

Kemine U, Gulfem B, Ahmet K, Igor L. Gestational trophoblastic diseases-diagnosis and risk factors: A case series. Int J Med Rev Case Rep. 2019; 3(8): 528-532. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors


Web Style

Kemine U, Gulfem B, Ahmet K, Igor L. Gestational trophoblastic diseases-diagnosis and risk factors: A case series. http://www.mdpub.net/?mno=29208 [Access: August 05, 2020]. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors


AMA (American Medical Association) Style

Kemine U, Gulfem B, Ahmet K, Igor L. Gestational trophoblastic diseases-diagnosis and risk factors: A case series. Int J Med Rev Case Rep. 2019; 3(8): 528-532. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors



Vancouver/ICMJE Style

Kemine U, Gulfem B, Ahmet K, Igor L. Gestational trophoblastic diseases-diagnosis and risk factors: A case series. Int J Med Rev Case Rep. (2019), [cited August 05, 2020]; 3(8): 528-532. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors



Harvard Style

Kemine, U., Gulfem, . B., Ahmet, . K. & Igor, . L. (2019) Gestational trophoblastic diseases-diagnosis and risk factors: A case series. Int J Med Rev Case Rep, 3 (8), 528-532. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors



Turabian Style

Kemine, Uzel, Basol Gulfem, Kale Ahmet, and Lakhno Igor. 2019. Gestational trophoblastic diseases-diagnosis and risk factors: A case series. International Journal of Medical Reviews and Case Reports, 3 (8), 528-532. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors



Chicago Style

Kemine, Uzel, Basol Gulfem, Kale Ahmet, and Lakhno Igor. "Gestational trophoblastic diseases-diagnosis and risk factors: A case series." International Journal of Medical Reviews and Case Reports 3 (2019), 528-532. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors



MLA (The Modern Language Association) Style

Kemine, Uzel, Basol Gulfem, Kale Ahmet, and Lakhno Igor. "Gestational trophoblastic diseases-diagnosis and risk factors: A case series." International Journal of Medical Reviews and Case Reports 3.8 (2019), 528-532. Print. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors



APA (American Psychological Association) Style

Kemine, U., Gulfem, . B., Ahmet, . K. & Igor, . L. (2019) Gestational trophoblastic diseases-diagnosis and risk factors: A case series. International Journal of Medical Reviews and Case Reports, 3 (8), 528-532. doi:10.5455/IJMRCR.gestational-trophoblastic-diseases-risk-factors